Journal
ANTIOXIDANTS
Volume 12, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/antiox12030711
Keywords
fatty acids; fatty liver; inflammation; metabolic syndrome; oxylipins
Ask authors/readers for more resources
Non-alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of hepatic fat. This study investigated the plasma levels of oxylipins, free polyunsaturated fatty acids (PUFA), and markers of lipid peroxidation in NAFLD patients. The results showed that severe NAFLD patients had higher levels of oxylipins, saturated oxylipins, and free PUFA, suggesting an association between inflammation, fatty acid oxidation dysregulation, and NAFLD progression.
Hepatic fat accumulation is the hallmark of non-alcoholic fatty liver disease (NAFLD). Our aim was to determine the plasma levels of oxylipins, free polyunsaturated fatty acids (PUFA) and markers of lipid peroxidation in patients with NAFLD in progressive stages of the pathology. Ninety 40-60-year-old adults diagnosed with metabolic syndrome were distributed in without, mild, moderate or severe NAFLD stages. The free PUFA and oxylipin plasma levels were determined by the UHPLC-MS/MS system. The plasma levels of oxylipins produced by cyclooxygenases, lipoxygenases and cytochrome P450, such as prostaglandin 2 alpha (PGF2 alpha), lipoxinB4 and maresin-1, were higher in severe NAFLD patients, pointing to the coexistence of both inflammation and resolution processes. The plasma levels of the saturated oxylipins 16-hydroxyl-palmitate and 3-hydroxyl-myristate were also higher in the severe NAFLD patients, suggesting a dysregulation of oxidation of fatty acids. The plasma 12-hydroxyl-estearate (12HEST) levels in severe NAFLD were higher than in the other stages, indicating that the hydroxylation of saturated fatty acid produced by reactive oxygen species is more present in this severe stage of NAFLD. The plasma levels of 12HEST and PGF2 alpha are potential candidate biomarkers for diagnosing NAFLD vs. non-NAFLD. In conclusion, the NAFLD progression can be monitored by measuring the plasma levels of free PUFA and oxylipins characterizing the different NAFLD stages or the absence of this disease in metabolic syndrome patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available